Astellas is aiding Vir Biotechnology’s oncology pivot with a $1.7 billion global collaboration focused on a potential best-in-class T-cell engager (TCE) for prostate cancer. | Astellas is aiding Vir ...

In a new study published in the journal Nature Genetics, Haolong Li, PhD, a researcher at Fred Hutch Cancer Center, and colleagues developed a way to monitor androgen receptor levels inside living ...

The Prostate Cancer Foundation (PCF) today announced a $10 million unrestricted gift from an anonymous donor to launch a ...

Significantly less progression, especially unstable lesions, with relugolix versus leuprol ...

Prostate cancer is one of the most common cancers and the second leading cause of cancer-related death in men worldwide. However, the mechanisms controlling the early stages of prostate cancer ...

CLEVELAND - Prostate cancer is the second leading cause of cancer-related deaths in men with an estimated 192,280 new cases diagnosed in the US in 2009 (Jemal 2009). Diet is considered one of the most ...

ADT with leuprolide was tied to increased coronary plaque vs relugolix in prostate cancer. What does this mean for CV risk?

The NanoKnife system employs non-thermal IRE ablation to destroy tumour cells while preserving surrounding anatomy.

Oric Pharmaceuticals (NASDAQ:ORIC) used a fireside chat at the Guggenheim Biotech Conference to outline development ...

Concentration of plastics was 2.5 times higher in cancerous tissue versus benign tissue ...